Tommaso Caravita
Research Subjects
Tommaso Caravita has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Paolo de Fabritiis
Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy
5 shared publications Agostina Siniscalchi
Ematologia Ospedale S. Eugenio – Università Tor Vergata Roma Italy
3 shared publications- Mario Boccadoro
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
2 shared publications - Massimo Offidani
Hematology Unit AOU delle Marche Ancona Italy
2 shared publications Roberto Stasi
Department of Medical Sciences, Ospedale "Regina Apostolorum", Albano Laziale, Italy
2 shared publications- Sergio Amadori
Tor Vergata University Hospital, Roma, Italy
2 shared publications
Latest Publications
- Open Access
- 13 March 2020
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 29 (1) , 27-31
Onset and Progression of Precancerous Lesions on Gastric Mucosa of Patients Treated for Gastric Lymphoma
Background and Aims: Patients with primary gastric lymphoma are at an increased risk of developing gastric cancer. Data on gastric precancerous lesions development in these patients are scanty. We assessed gastric precancerous lesions in a cohort of patients with primary lymphoma. Methods: Data of patients with primary gastric lymphoma [mucosa-associated lymphoid tissue (MALT)- lymphoma or diffuse large B-cell lymphoma (DLBCL)] were analysed. Multiple (>10) biopsies were performed on gastric mucosa at each endoscopic control, beyond macroscopic lesions. Presence and distribution of intestinal metaplasia (IM) at baseline, the onset at follow-up, and progression through the stomach or transformation in the incomplete IM type were assessed. The onset of neoplastic lesions was recorded. Results: Data of 50 patients (mean age of 63.6 ± 10.7 years; M/F: 25/25), including 40 with MALT-lymphoma and 10 with DLBCL, with median follow-up of 30.5 months (range: 9-108) and a median of 6 endoscopic controls (range: 3-14) were evaluated. At entry, IM was present in 12 (24%), and it developed in other 22 (57.9%) patients at a median follow-up of 6 (range: 3-40) months. Overall, progression of IM was observed in 7 (21.2%) cases, including extension in the stomach (n=5) or transformation into the incomplete type (n=2). Low-grade dysplasia was detected in 4, and indefinite dysplasia in other 7 patients. In one patient, low-grade dysplasia had progressed to high-grade and gastric adenocarcinoma of the fundus. Conclusions: Our data found a frequent onset and rapid progression of precancerous lesions on gastric mucosa of lymphoma patients. This observation could explain the increased incidence of metachronous gastric cancer in these patients.
- 13 March 2020
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 29 (1) , 27-31
Open AccessOnset and Progression of Precancerous Lesions on Gastric Mucosa of Patients Treated for Gastric Lymphoma
Background and Aims: Patients with primary gastric lymphoma are at an increased risk of developing gastric cancer. Data on gastric precancerous lesions development in these patients are scanty. We assessed gastric precancerous lesions in a cohort of patients with primary lymphoma. Methods: Data of patients with primary gastric lymphoma [mucosa-associated lymphoid tissue (MALT)- lymphoma or diffuse large B-cell lymphoma (DLBCL)] were analysed. Multiple (>10) biopsies were performed on gastric mucosa at each endoscopic control, beyond macroscopic lesions. Presence and distribution of intestinal metaplasia (IM) at baseline, the onset at follow-up, and progression through the stomach or transformation in the incomplete IM type were assessed. The onset of neoplastic lesions was recorded. Results: Data of 50 patients (mean age of 63.6 ± 10.7 years; M/F: 25/25), including 40 with MALT-lymphoma and 10 with DLBCL, with median follow-up of 30.5 months (range: 9-108) and a median of 6 endoscopic controls (range: 3-14) were evaluated. At entry, IM was present in 12 (24%), and it developed in other 22 (57.9%) patients at a median follow-up of 6 (range: 3-40) months. Overall, progression of IM was observed in 7 (21.2%) cases, including extension in the stomach (n=5) or transformation into the incomplete type (n=2). Low-grade dysplasia was detected in 4, and indefinite dysplasia in other 7 patients. In one patient, low-grade dysplasia had progressed to high-grade and gastric adenocarcinoma of the fundus. Conclusions: Our data found a frequent onset and rapid progression of precancerous lesions on gastric mucosa of lymphoma patients. This observation could explain the increased incidence of metachronous gastric cancer in these patients.
- 1 June 2012
- Published by Wiley in European Journal of Haematology
- Vol. 89 (3) , 276-277
Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations
- 1 June 2012
- Published by Wiley in European Journal of Haematology
- Vol. 89 (3) , 276-277
Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations
- 21 February 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (6) , 814-818
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
- 21 February 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (6) , 814-818
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
- 16 July 2009
- Published by Springer Nature in International Journal of Hematology
- Vol. 90 (2) , 270-272
High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients
- 16 July 2009
- Published by Springer Nature in International Journal of Hematology
- Vol. 90 (2) , 270-272
High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients
- 11 June 2009
- Published by BMJ in BMJ Case Reports
- Vol. 2009
Management of immune thrombocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer: Figure 1
Immune thrombocytopoenia (ITP) is one of the most common autoimmune manifestations of B cell lymphoproliferative diseases. The association with multiple myeloma (MM) and solid tumours is rare. Here, a case of ITP associated with asymptomatic multiple myeloma and colon carcinoma, refractory to standard therapy and responsive to rituximab, is described. ITP should be considered in the differential diagnosis of thrombocytopoenia in MM and colon cancer. Understanding of the potential risk and reversibility of ITP should aid in the management of these patients.
- 11 June 2009
- Published by BMJ in BMJ Case Reports
- Vol. 2009
Management of immune thrombocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer: Figure 1
Immune thrombocytopoenia (ITP) is one of the most common autoimmune manifestations of B cell lymphoproliferative diseases. The association with multiple myeloma (MM) and solid tumours is rare. Here, a case of ITP associated with asymptomatic multiple myeloma and colon carcinoma, refractory to standard therapy and responsive to rituximab, is described. ITP should be considered in the differential diagnosis of thrombocytopoenia in MM and colon cancer. Understanding of the potential risk and reversibility of ITP should aid in the management of these patients.
- 3 November 2008
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 43 (7) , 587-588
High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia
- 3 November 2008
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 43 (7) , 587-588
High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia
- 1 July 2006
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 3 (7) , 374-387
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Bortezomib is a protease inhibitor and is the first compound in this drug class to be used in clinical practice, with trials demonstrating efficacy in patients with relapsed/refractory multiple myeloma. Mature clinical data on the efficacy of bortezomib in solid tumors are not yet available, but early clinical data indicate this could be a promising drug for the treatment of advanced solid tumors. This Review summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors. Proteasome inhibition represents a new anticancer approach, with the potential effect of arresting tumor growth, metastasis and angiogenesis through the activation of multiple mechanisms. Bortezomib is a biologically active agent, producing predictable, dose-related and reversible proteasome inhibition; it has shown antitumor activity in various malignancies and is the first proteasome inhibitor to be used in clinical practice. Several trials demonstrated that bortezomib is relatively well tolerated, causing manageable nonhematologic and hematologic toxicity. The drug was approved in 2003 by the FDA for the treatment of patients with multiple myeloma who had received at least two prior therapies and demonstrated disease progression on the last therapy; its application was expanded recently for second-line treatment. This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors.
- 1 July 2006
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 3 (7) , 374-387
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Bortezomib is a protease inhibitor and is the first compound in this drug class to be used in clinical practice, with trials demonstrating efficacy in patients with relapsed/refractory multiple myeloma. Mature clinical data on the efficacy of bortezomib in solid tumors are not yet available, but early clinical data indicate this could be a promising drug for the treatment of advanced solid tumors. This Review summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors. Proteasome inhibition represents a new anticancer approach, with the potential effect of arresting tumor growth, metastasis and angiogenesis through the activation of multiple mechanisms. Bortezomib is a biologically active agent, producing predictable, dose-related and reversible proteasome inhibition; it has shown antitumor activity in various malignancies and is the first proteasome inhibitor to be used in clinical practice. Several trials demonstrated that bortezomib is relatively well tolerated, causing manageable nonhematologic and hematologic toxicity. The drug was approved in 2003 by the FDA for the treatment of patients with multiple myeloma who had received at least two prior therapies and demonstrated disease progression on the last therapy; its application was expanded recently for second-line treatment. This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors.